As tumors develop, they evolve genetically. How does the immune system act when faced with tumor cells? How does it exert pressure on the genetic diversity of cancer cells? Scientists from the Institut Pasteur and Inserm used in vivo video techniques and cell-specific staining to visualize the action of immune cells in response to the proliferation of cancer cells. The findings have been published in the journal Science Immunology...
Researchers from Inserm, CNRS, Paris-Sud University, Gustave Roussy, and Institut Curie have identified a new agent in regulating PD-L1 gene expression: the eIF4F complex, which plays a role in controlling protein synthesis.
Decreased jaw bone volume in edentate patients is the main difficulty which arises when fitting dental implants. Bone grafting is currently the most frequent solution for this problem. However, this method has several disadvantages, such as deterioration of the bone graft over time. Between 2010 and 2015, Pierre Layrolle, Inserm researcher, working with Norwegian and German teams as part of the REBORNE European project, tested an innovative technique for...
Liver cancer is the second most deadly form of cancer worldwide. While the majority of patients develop hepatocellular carcinoma, 10 to 20 % develop the second type of primary liver cancer: intrahepatic cholangiocellular carcinoma – a highly-invasive cancer of the liver bile ducts. And while both these tumor types have some risk factors in common, the number of patients presenting with intrahepatic cholangiocellular carcinoma has seen a marked increase...
Prof. Alexander Loupy, Hospital Necker Children AP-HP and Prof. Carmen Lefaucheur, the Saint-Louis Hospital AP-HP and the University Paris Diderot in the Cardiovascular Research Center (Inserm / Paris Descartes University), showed, in an article published in the journal New England Journal of Medicine September 20, 2018, the latest advances and applications of artificial intelligence carried out in the field of transplantation, including the diagnosis and the treatment of allograft rejection.
The digestive oncology teams from European Georges Pompidou Hospital, Cochin and Ambroise Paré AP-HP, and laboratory "Information Sciences and personalized medicine" of 1138 Unit Research Center Cordeliers INSERM and Paris-Descartes University, have developed an artificial intelligence system that predict therapeutic response to preoperative chemoradiotherapy in patients monitored for rectal cancer. The work, coordinated by Dr. Jean-Emmanuel Bibault of oncology radiotherapy European Hospital Georges Pompidou AP-HP, would propose a conservative treatment...
A study published in The Lancet Oncology establishes for the first time that artificial intelligence can process medical images to extract biological and clinical information. By designing an algorithm and developing it to analyse CT scan images, medical researchers at Gustave Roussy, CentraleSupélec, Inserm, Paris-Sud University and TheraPanacea (spin-off from CentraleSupélec specialising in artificial intelligence in oncology-radiotherapy and precision medicine) have created a so-called radiomic signature. This signature defines...
Over 3 million people in France are currently living with cancer or have recovered from it. While the number of new cases diagnosed each year continues to increase, the advances made in diagnosis and treatment have made it possible to push back mortality. The disease remains a difficult ordeal for those affected, both physically and psychologically, and is also synonymous with social and professional disruption. In order to study the evolution of...
Three new members have been isolated and added to the Pandoravirus family by researchers at the Structural and Genomic Information Laboratory (CNRS/Aix‐Marseille Université), working with partners at the Large Scale Biology Laboratory (CEA/Inserm/Université Grenoble‐Alpes) and at CEA-Genoscope. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised the scientists when they were discovered a few years ago. In the 11 June 2018...
What if immune system efficacy against cancerous cells could be reinforced by a diet in which calories are not reduced but nutrients are precisely determined? This what Inserm researchers from Université Côte d’Azur, through a study of the effects of restrictive diets on tumor growth in mice, have been exploring. They have observed that a low-protein diet restricts tumor development by increasing immune response. The findings, to be published...